The comparative study of the impact of differences in the timing of oral DPP4 inhibitor in type 2 diabetes is on the glycemic control.

The comparative study of the impact of differences in the timing of oral DPP4 inhibitor in type 2 diabetes is on the glycemic control. - Oral timing of DPP4 inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018990

Enrollment

Registered

2016-03-31

Start date

2015-10-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Differences of oral timing Differences of oral timing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c < 7.5%

Exclusion criteria

Exclusion criteria: What you are using three or more agents of oral hypoglycemic agents other than DPP4 inhibitor.

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Countries

Japan

Contacts

Public ContactMuhei Tanaka

Kyoto Prefectural University of Medicine Department of Endocrinology and Metabolism

muhei-t@koto.kpu-m.ac.jp075-251-5506

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026